看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。% u4 H5 |0 M; D: {: s7 |- b
1 J9 t- X A: M# ^$ J* c! E9 o7 x1 ~
$ o, J$ W: Q! R2 ~; c J! B7 }Currently available feasibility data for possible combination strategies.
5 X2 p) k* N! p3 t1 y% Y( Q————————————————————————————————
$ `0 G; g% I$ h# MCombination Feasibility according to preliminary data
/ G: S" M$ a& i——————————————————————————————————
; V" q6 j3 h, {) w2 E* r5 @9 pBevacizumab + sorafenib Yes, reduced dose " z& j; u8 k! f6 Y1 \( T s
Bevacizumab + sunitinib† No - t. X3 B8 p' \4 z
Bevacizumab + temsirolimus Yes
, _& B G* q$ r5 O8 A4 |5 F3 _Bevacizumab + everolimus Yes
+ s; D. ^( d5 ~# \$ ]/ {Sorafenib + sunitinib ?
0 l. Y, P0 o }+ q5 { hSorafenib + temsirolimus Yes, reduced dose
8 h* Q* u- R, R- o, z0 t uSorafenib + everolimus Yes, reduced dose
3 l! Y; _2 q) E; W% V% Q7 q* YSunitinib + temsirolimus† No % Z! T1 V/ ]) u$ A, f+ k+ B" b
Sunitinib + everolimus ?
5 e* `9 @) u, Q& VTemsirolimus + everolimus ? f. {4 N! E/ p3 A
————————————————————6 I" z% H: ~$ j0 E
†Led to US FDA warning.
* @+ L! e8 t9 C S?: As yet unattempted combination.
0 ^0 y- Z, C# `0 Q' T |